FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, announced significant advancements in its Bone Marrow Organoid (BMO) platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline.
The company reported that pre-IND animal trials demonstrated that transplantation of BMOs into a xenografted melanoma mouse model significantly reduced tumor size. Additionally, the BMOs enable efficient ex vivo gene editing, allowing for swift and targeted therapeutic interventions before transplantation. Furthermore, these organoids can be cryopreserved, offering a scalable and readily available treatment option for bone marrow transplantation.
FibroBiologics claims that its BMO platform has the potential to regenerate desired immune cell types, counter age-related immune system decline, and restore immune function in patients with compromised immune systems. The company also suggests that this approach could enable the in-vivo generation of advanced cell therapies, such as CAR-T and CAR-NK cells, directly within patients.
These developments mark a critical step toward clinical translation of the BMO technology, supporting the company’s pre-IND enabling development efforts.
FibroBiologics holds over 270 patents issued and pending, focusing on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.
